RA Capital Management »

Grail shares owned by RA Capital Management

Quarter-by-quarter ownership of Grail (GRAL) shares owned by RA Capital Management from 13F filings

Historical chart of RA Capital Management investment in Grail

Tip: Access up to 7 years of quarterly data

All positions including Grail held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Grail by RA Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $37M 428k 85.59

More positions owned by RA Capital Management

Ascendis Pharma A/s - SH (ASND)
Cidara Therapeutics SH (CDTX)
Rhythm Pharmaceuticals SH (RYTM)
Avidity Biosciences SH (RNA)
Vaxcyte SH (PCVX)
Sionna Therapeutics SH (SION)
Newamsterdam Pharma Co Nv SH (NAMS)
Tyra Biosciences SH (TYRA)
Wave Life Sciences SH (WVE)
Mineralys Therapeutics SH (MLYS)
Edgewise Therapeutics SH (EWTX)
Septerna SH (SEPN)
Nuvalent Inc-a SH (NUVL)
Disc Medicine SH (IRON)
Janux Therapeutics SH (JANX)

View all positions for RA Capital Management

Top funds holding Grail

BlackRock
Farallon Capital Management
Baker Bros. Advisors
Vanguard Group
PRIMECAP Management Company
State Street Corporation
Susquehanna International
CRCM
Fort Hoosac Management
Deep Track Capital
Geode Capital Management
Goldman Sachs Group
Alyeska Investment Group
RA Capital Management
Sessa Capital IM

View all funds holding Grail